|D002925||Ciliary Motility Disorders NIH||1.00|
There is one clinical trial.
Participants will be randomized in a 1:1 ratio to receive Colchicine plus current care per UCLA treating physicians versus current care per UCLA treating physicians alone (control arm). Importantly, this adaptive trial design allows for patients in either study arm to receive other investigational drugs for COVID-19 as new science emerges.
Description: Number of participants experiencing any of the following: All-cause mortality, need for mechanical ventilation, or need for mechanical circulatory support (MCS)Measure: Composite of all-cause mortality, need for mechanical ventilation, or need for mechanical circulatory support (MCS) Time: 90 Days
Description: Change from initial troponin level to maximum level of troponin among measures taken during hospitalization and at 30 daysMeasure: Delta (peak minus baseline) troponin level Time: Baseline (Day 1), Day 30, Days 3 and 7 if hospitalized
Description: Change from baseline BNP level (Day 1) to maximum level of BNP among measures taken during hospitalization and at 30 daysMeasure: Delta (baseline to peak) brain natriuretic peptide (BNP) level Time: Baseline (Day 1), Day 30, Days 3 and 7 if hospitalized
Description: Number of participants experiencing LVEF of < 50% on echocardiogram with failure to show an improvement of ≥ 5% at 30 daysMeasure: Change in left ventricular ejection fraction (LVEF) on echocardiography Time: Baseline, Day 30
Description: D-Dimer is a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis, so named because it contains two D fragments of the fibrin protein joined by a cross-linkMeasure: Delta (peak minus baseline) D-Dimer inflammatory biomarker level Time: Baseline (Day 1), Day 30, Days 3 and 7 if hospitalized
Description: Number of participants released and re-admitted to the hospital within 90 days of enrollmentMeasure: Re-hospitalization at 90 days Time: 90 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports